Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 27
- Registration Number
- NCT03958955
- Locations
- 🇩🇰
LEO Pharma Investigational site, Hellerup, Denmark
🇩🇪LEO Pharma Investigational Site, Oldenburg, Germany
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 15
- Registration Number
- NCT03898583
- Locations
- 🇩🇪
LEO Pharma investigational site, Hamburg, Germany
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 46
- Registration Number
- NCT03826901
- Locations
- 🇨🇦
LEO Pharma investigational site, Montréal, Quebec, Canada
A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 66
- Registration Number
- NCT03812198
- Locations
- 🇬🇧
LEO Pharma Investigational Site, Leeds, United Kingdom
Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 182
- Registration Number
- NCT03806790
- Locations
- 🇯🇵
Leo Pharma Investigational Site, Setagaya, Tokyo, Japan
A Study to Learn More About the Relationship Between the Development of a Gap in the Upper Lip (Cleft Lip) or in the Roof of the Mouth (Cleft Palate) in Newborns and the Use of Glucocorticoids by the Mother During Pregnancy: a Meta-analysis
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 99999
- Registration Number
- NCT03788863
- Locations
- 🇩🇪
Many locations, Multiple Locations, Germany
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 277
- Registration Number
- NCT03761537
- Locations
- 🇬🇧
Leo Pharma Investigationel Site, Wakefield, United Kingdom
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 251
- Registration Number
- NCT03725722
- Locations
- 🇦🇺
Leo Pharma Investigational Site 1, Kogarah, Australia
🇨🇦Leo Pharma Investigational Site, Toronto, Ontario, Canada
Investigation of Flare and Remission in Subjects With Atopic Dermatitis
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- LEO Pharma
- Registration Number
- NCT03710044
- Locations
- 🇳🇱
Investigational site, Rotterdam, Netherlands
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 258
- Registration Number
- NCT03683719
- Locations
- 🇩🇰
LEO Pharma Investigational Site, Herlev, Denmark
🇩🇪Leo Pharma Investigational Site, Wuppertal, Germany
© Copyright 2024. All Rights Reserved by MedPath